Mid-term implant survival, clinical and patient reported outcomes following silastic arthroplasty for the treatment of end stage Hallux rigidus
E. Drampalos, T. Karim, T Clough
Aim: To examine the mid-term survival, clinical and patient reported outcomes of the silastic 1st metatarsophalangeal joint replacement for the treatment of end stage hallux rigidus.
Methods: We reviewed 83 consecutive silastic arthroplasties performed in 79 patients for end stage hallux rigidus. There were 3 men and 76 women; mean age 63 years (range 45-78 years). No patient was lost to follow up. Average follow-up was 5.3 years (1.1-11.3 years). The EQ 5D-5L Health index, Manchester-Oxford Foot Questionnaire (MOXFQ), visual analogue scale (VAS) of pain and overall satisfaction rate (Likert scale) were collected for patient reported outcomes.
Results: 2 patients required revision; 1 for early infection (2 months) and 1 for stem breakage (10 years 1 month). 5 patients reported lateral metatarsalgia, 2 patients reported neuropathic pain, 6 patients developed superficial infection which fully responded to oral antibiotics, and 1 patient developed interphalangeal joint pain. 2 patients died in the cohort. Pre-operative mean MOXFQ was 44, mean EQ5D Index was 0.564 and VAS was 6.97. At mean follow-up of 5.3 years, the mean MOXFQ was 12.7 (0-57), the mean EQ5D Index was 0.851 (-0.02-1) and the mean VAS was 1.67 (0-8). The mean range of motion was 35° (30° dorsiflexion and 5° plantarflexion). The overall satisfaction rate was 90.2%. The implant survival rate was 97.6%.
Conclusions: The silastic big toe arthroplasty offers excellent clinical mid term survival and functional outcomes and could be considered as an attractive alternative to traditional fusion for end stage hallux rigidus.
Print